OTCMKTS:PHGUF

Pharming Group (PHGUF) Stock Forecast, Price & News

$1.30

0.00 (0.00%)

(As of 09/29/2023 ET)

Compare

Today's Range: $1.30
▼
$1.30
50-Day Range: $1.23
▼
$1.40
52-Week Range: $0.96
▼
$1.59

Volume: N/A
Average Volume: 485 shs
Market Capitalization: $848.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Earnings Headlines Short Interest

About Pharming Group (OTCMKTS:PHGUF) Stock

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

PHGUF Price History

30 days | 90 days | 365 days | Advanced Chart

PHGUF Stock News Headlines

September 22, 2023 | finance.yahoo.com

Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?

September 9, 2023 | msn.com

Pharming Group: Pipeline Progresses With APDS Phase 3 Initiation

October 1, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 9, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Pharming Group (PHAR)

August 9, 2023 | markets.businessinsider.com

Pharming Group NV American Depositary Shares Repr 10 Shs Reg S

August 4, 2023 | msn.com

Pharming Group N.V. reports Q2 results

May 15, 2023 | markets.businessinsider.com

RBC Capital Sticks to Their Buy Rating for Pharming Group (PHGUF)

May 12, 2023 | msn.com

Pharming Group N.V. GAAP EPS of $0.02, revenue of $42.5M misses by $6M

October 1, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

May 11, 2023 | benzinga.com

Pharming Group shares are trading lower after the company reported a year-over-year decrease in Q1 EPS and revenue.

May 11, 2023 | markets.businessinsider.com

Pharming Group NV American Depositary Shares Repr 10 earnings: here's what Wall Street expects

May 11, 2023 | finance.yahoo.com

Pharming Group reports financial results for the first quarter of 2023

May 8, 2023 | finance.yahoo.com

Pharming Group's (AMS:PHARM) investors will be pleased with their decent 51% return over the last year

April 26, 2023 | finanznachrichten.de

Pharming Group N.V.: Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023

April 26, 2023 | finance.yahoo.com

Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023

April 19, 2023 | finanznachrichten.de

Pharming Group: Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023

April 19, 2023 | finanznachrichten.de

Pharming Group N.V.: Notice of First Quarter 2023 Results

April 19, 2023 | finance.yahoo.com

Notice of First Quarter 2023 Results

April 19, 2023 | finance.yahoo.com

Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023

April 11, 2023 | finance.yahoo.com

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

April 5, 2023 | finance.yahoo.com

Pharming Group announces the filing of its 2022 Annual Report and Form 20-F

March 30, 2023 | finance.yahoo.com

Pharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days

March 27, 2023 | finance.yahoo.com

FDA Approves Pharming's Immune Disorder Drug, As First APDS Therapy

March 13, 2023 | finance.yahoo.com

Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank in light of US Government announcement

February 28, 2023 | finanznachrichten.de

Pharming Group N.V.: Notice of Full Year 2022 financial results

February 28, 2023 | finance.yahoo.com

Notice of Full Year 2022 financial results

February 21, 2023 | finanznachrichten.de

Pharming Group N.V.: Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

See More Headlines

Receive PHGUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

PHGUF Company Calendar

Last Earnings: 3/05/2015
Today: 10/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:PHGUF
Previous Symbol: OTC:PHGUF
CUSIP: N/A
CIK: N/A
Web: www.pharming.com
Phone: (171) 524-7400
Fax: 31-0-71-524-7445
Employees: 332
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $13.67 million
Net Margins: -7.96%
Pretax Margin: 7.29%
Return on Equity: -8.15%
Return on Assets: -4.00%

Debt

Debt-to-Equity Ratio: 0.83
Current Ratio: 4.51
Quick Ratio: 3.69

Sales & Book Value

Annual Sales: $205.62 million
Price / Sales: 4.12
Cash Flow: $0.04 per share
Price / Cash Flow: 31.57
Book Value: $0.31 per share
Price / Book: 4.19

Miscellaneous

Outstanding Shares: 652,410,000
Free Float: N/A
Market Cap: $848.13 million
Optionable: Not Optionable
Beta: 1.10

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Sijmen de Vries M.B.A. (Age 64)
M.D., MBA, Pres, CEO & Exec. Director
Comp: $1.18M

Mr. Jeroen Wakkerman (Age 54)
Chief Financial Officer

Ms. Mireille Sanders M.Sc. (Age 55)
Chief Operations Officer

Susanne Embleton
Investor Relations Mang.

Mr. Ruud Van Outersterp (Age 59)
Chief Ethics & Compliance Officer

Dr. Anurag Relan M.D. (Age 51)
MPH, Chief Medical Officer

Mr. Stephen Toor (Age 52)
Chief Commercial Officer & GM Americas

Dr. Alexander Breidenbach M.B.A.
Chief Bus. Officer

Dr. Bruno M. L. Giannetti (Age 71)
Consultant

Key Competitors

View All Competitors

PHGUF Stock - Frequently Asked Questions

How have PHGUF shares performed in 2023?: Pharming Group's stock was trading at $1.1499 at the beginning of 2023. Since then, PHGUF stock has increased by 13.1% and is now trading at $1.30.
View the best growth stocks for 2023 here.
How were Pharming Group's earnings last quarter?: Pharming Group (OTCMKTS:PHGUF) issued its earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a negative trailing twelve-month return on equity of 8.15% and a negative net margin of 7.96%.
What is Pharming Group's stock symbol?: Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF."
How do I buy shares of Pharming Group?: Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharming Group's stock price today?: One share of PHGUF stock can currently be purchased for approximately $1.30.
How much money does Pharming Group make?: Pharming Group (OTCMKTS:PHGUF) has a market capitalization of $848.13 million and generates $205.62 million in revenue each year. The biotechnology company earns $13.67 million in net income (profit) each year or ($0.03) on an earnings per share basis.
How many employees does Pharming Group have?: The company employs 332 workers across the globe.
How can I contact Pharming Group?: Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The official website for the company is www.pharming.com. The biotechnology company can be reached via phone at (171) 524-7400, via email at investor@pharming.com, or via fax at 31-0-71-524-7445.

This page (OTCMKTS:PHGUF) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial